| Judul | Therapeutic Radionuclides in Nuclear Medicine / Edited by: Marc Pretze; Jörg Kotzerke |
| Pengarang | Pretze, Marc Kotzerke, Jörg |
| EDISI | - |
| Penerbitan | Basel : MDPI, 2025 |
| Deskripsi Fisik | 194p. :Ill. |
| ISBN | 978-3-7258-2937-8 |
| Subjek | THERAPEUTICS RADIOISOTOPES NUCLEAR MEDICINE |
| Catatan | Recently, the theranostic principle has been used with tumor receptor-specific radiopharmaceuticals containing therapeutic nuclides, such as 161Tb, 177Lu, 188Re, 212Pb, and 225Ac. The production mode, availability, and costs of radionuclides have a significant impact on their clinical use and are often bottlenecks for broader applications. Therefore, cyclotron-produced neutrons could open a new era for producing relevant radionuclides. The identification of tumor-specific binding sites, the development of tumor-addressing conjugates, opportunities for enhanced target enrichment, and the protection of critical organs define the potential of therapeutic radiopharmaceuticals. The combination of radiotherapeutics with other pharmaceuticals to modulate the target or repair systems exploits synergistic effects. Combining radiotherapeutics with the body's immune system or immunotherapeutics raises hopes for immunization against cancer and could explain the success of targeted alpha therapy vs. targeted beta therapy. |
| Bentuk Karya | Tidak ada kode yang sesuai |
| Target Pembaca | Tidak ada kode yang sesuai |
| Lokasi Akses Online |
https://www.mdpi.com/books/reprint/10416-therapeutic-radionuclides-in-nuclear-medicine |
| No Barcode | No. Panggil | Akses | Lokasi | Ketersediaan |
|---|---|---|---|---|
| 295626192 | 616 The | Baca Online | Perpustakaan Pusat - Online Resources Ebook |
Tersedia |
| Tag | Ind1 | Ind2 | Isi |
| 001 | INLIS000000000169963 | ||
| 005 | 20260905015457 | ||
| 007 | ta | ||
| 008 | 260905################|##########|#|## | ||
| 020 | # | # | $a 978-3-7258-2937-8 |
| 035 | # | # | $a 0010-0926000257 |
| 082 | # | # | $a 616 |
| 084 | # | # | $a 616 The |
| 245 | # | # | $a Therapeutic Radionuclides in Nuclear Medicine /$c Edited by: Marc Pretze; Jörg Kotzerke |
| 250 | # | # | $a - |
| 260 | # | # | $a Basel :$b MDPI,$c 2025 |
| 300 | # | # | $a 194p. : $b Ill. |
| 505 | # | # | $a Recently, the theranostic principle has been used with tumor receptor-specific radiopharmaceuticals containing therapeutic nuclides, such as 161Tb, 177Lu, 188Re, 212Pb, and 225Ac. The production mode, availability, and costs of radionuclides have a significant impact on their clinical use and are often bottlenecks for broader applications. Therefore, cyclotron-produced neutrons could open a new era for producing relevant radionuclides. The identification of tumor-specific binding sites, the development of tumor-addressing conjugates, opportunities for enhanced target enrichment, and the protection of critical organs define the potential of therapeutic radiopharmaceuticals. The combination of radiotherapeutics with other pharmaceuticals to modulate the target or repair systems exploits synergistic effects. Combining radiotherapeutics with the body's immune system or immunotherapeutics raises hopes for immunization against cancer and could explain the success of targeted alpha therapy vs. targeted beta therapy. This reprint is dedicated to nuclear oncologists, health physicists, radiopharmacists, radiochemists, radiobiologists, and all other oncologists. We thank all our colleagues and would like to express our respect for their contributions to this reprint. |
| 650 | # | # | $a NUCLEAR MEDICINE |
| 650 | # | # | $a RADIOISOTOPES |
| 650 | # | # | $a THERAPEUTICS |
| 700 | 1 | # | $a Kotzerke, Jörg |
| 700 | 1 | # | $a Pretze, Marc |
| 856 | # | # | $a https://www.mdpi.com/books/reprint/10416-therapeutic-radionuclides-in-nuclear-medicine |
| 990 | # | # | $a 295626192 |
Content Unduh katalog
Karya Terkait :